212 related articles for article (PubMed ID: 36813377)
21. The hemostatic role of factor XI.
Puy C; Rigg RA; McCarty OJ
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
[TBL] [Abstract][Full Text] [Related]
22. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
23. Factor XI as a target for antithrombotic therapy.
Bane CE; Gailani D
Drug Discov Today; 2014 Sep; 19(9):1454-8. PubMed ID: 24886766
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
Pinto DJP; Orwat MJ; Smith LM; Quan ML; Lam PYS; Rossi KA; Apedo A; Bozarth JM; Wu Y; Zheng JJ; Xin B; Toussaint N; Stetsko P; Gudmundsson O; Maxwell B; Crain EJ; Wong PC; Lou Z; Harper TW; Chacko SA; Myers JE; Sheriff S; Zhang H; Hou X; Mathur A; Seiffert DA; Wexler RR; Luettgen JM; Ewing WR
J Med Chem; 2017 Dec; 60(23):9703-9723. PubMed ID: 29077405
[TBL] [Abstract][Full Text] [Related]
25. Evidence for factor IX-independent roles for factor XIa in blood coagulation.
Matafonov A; Cheng Q; Geng Y; Verhamme IM; Umunakwe O; Tucker EI; Sun MF; Serebrov V; Gruber A; Gailani D
J Thromb Haemost; 2013 Dec; 11(12):2118-27. PubMed ID: 24152424
[TBL] [Abstract][Full Text] [Related]
26. The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.
DeLoughery EP; Olson SR; Puy C; McCarty OJT; Shatzel JJ
Semin Thromb Hemost; 2019 Jul; 45(5):502-508. PubMed ID: 31216587
[TBL] [Abstract][Full Text] [Related]
27. The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.
Wu W; Li H; Navaneetham D; Reichenbach ZW; Tuma RF; Walsh PN
Blood; 2012 Jul; 120(3):671-7. PubMed ID: 22674803
[TBL] [Abstract][Full Text] [Related]
28. Factor XI/XIa Inhibitors: A New Approach to Anticoagulation.
Whiteson HZ; Frishman WH
Cardiol Rev; 2023 Dec; ():. PubMed ID: 38038437
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection.
Demoulin S; Godfroid E; Hermans C
J Thromb Haemost; 2021 Feb; 19(2):323-329. PubMed ID: 33047454
[TBL] [Abstract][Full Text] [Related]
30. Effect of factor XI inhibition on tumor cell-induced coagulation activation.
Mäder J; Rolling CC; Voigtländer M; Schulenkorf A; Lehr C; Regenhardt J; Bokemeyer C; Beckmann L; Langer F
J Thromb Haemost; 2024 Jan; 22(1):199-212. PubMed ID: 37751848
[TBL] [Abstract][Full Text] [Related]
31. Factor XI, a potential target for anticoagulation therapy for venous thromboembolism.
Li T; Liu J; Wu W
Front Cardiovasc Med; 2022; 9():975767. PubMed ID: 36386334
[TBL] [Abstract][Full Text] [Related]
32. Coagulation factor XI as a novel target for antithrombotic treatment.
Löwenberg EC; Meijers JC; Monia BP; Levi M
J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
[TBL] [Abstract][Full Text] [Related]
33. Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation.
Parunov LA; Liang Y; Lu Q; Shibeko AM; Tucker EI; Lee TK; Ataullakhanov FI; Scott DE; Ovanesov MV
Blood Adv; 2023 Jun; 7(11):2622-2631. PubMed ID: 36724509
[TBL] [Abstract][Full Text] [Related]
34. Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism.
Cohen O; Ageno W
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):495-505. PubMed ID: 36485148
[TBL] [Abstract][Full Text] [Related]
35. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery.
Yamashita A; Nishihira K; Kitazawa T; Yoshihashi K; Soeda T; Esaki K; Imamura T; Hattori K; Asada Y
J Thromb Haemost; 2006 Jul; 4(7):1496-501. PubMed ID: 16839345
[TBL] [Abstract][Full Text] [Related]
36. Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).
Al-Horani RA
Expert Opin Ther Pat; 2020 Jan; 30(1):39-55. PubMed ID: 31847619
[No Abstract] [Full Text] [Related]
37. Predictive value for increased activated factor XI activity in acute venous thromboembolism.
Nagy M; Robles AP; Visser M; Koeck T; Ten Cate V; Ten Cate-Hoek AJ; Schwers S; Heitmeier S; Ten Cate H; Wild PS; Spronk HMH
J Thromb Haemost; 2023 Jun; 21(6):1610-1622. PubMed ID: 37003466
[TBL] [Abstract][Full Text] [Related]
38. Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.
Visser M; van Oerle R; Ten Cate H; Laux V; Mackman N; Heitmeier S; Spronk HMH
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):103-111. PubMed ID: 31766871
[TBL] [Abstract][Full Text] [Related]
39. The rebirth of the contact pathway: a new therapeutic target.
Srivastava P; Gailani D
Curr Opin Hematol; 2020 Sep; 27(5):311-319. PubMed ID: 32740037
[TBL] [Abstract][Full Text] [Related]
40. Coagulation factors XI and XII as possible targets for anticoagulant therapy.
Kluge KE; Seljeflot I; Arnesen H; Jensen T; Halvorsen S; Helseth R
Thromb Res; 2022 Jun; 214():53-62. PubMed ID: 35490644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
